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Plasma preparation
Plasma was prepared by centrifugation of citrated blood (Coagulation monovette, Sarstedt) for 10 min at 3000 g. Supernatant plasma was collected and re-centrifuged for 3 min at 10.000 g. Double-centrifuged platelet-poor plasma was stored in aliquots at -70°C.
TMA patient plasma samples
We used a previously described collection of plasma samples from patients with acute TMA [15] . Plasma samples were selected from patients referred for ADAMTS13 activity testing for diagnostic purposes to the Hemostasis Research Laboratory, Department of Hematology, Bern University Hospital and the University of Bern (Bern, Switzerland). All patients had received a diagnosis of TMA by their referring physicians defined by microangiopathic hemolytic anemia with schistocytes on the blood smear and thrombocytopenia with or without clinically apparent ischemic organ dysfunction. In patients treated by plasma exchange therapy and fresh frozen plasma replacement, plasma was collected before initiation of plasma therapy. The plasma collection also included plasma from 10 healthy donors, which served as control samples for TMA patient plasma analysis. All samples were stored in aliquots at -70°C. The study was approved by the responsible Ethics Committee (Kantonale Ethikkommission, Bern, Switzerland).
Commercial DNase1
We used recombinant human DNase1 (rhDNase1, dornase alpha, Pulmozyme; Roche) as commercial source of DNase1. Dilutions of DNase1 were made in phosphate-buffered saline (PBS) containing 0.1 % BSA.
Actin:G1 complex
Rabbit skeletal muscle actin was prepared from dried acetone powder obtained from fresh rabbit psoas muscle as previously described [24] . G-actin was stored in G-buffer containing 5 mM HEPES pH 7.4, 0.1 mM CaCl 2 , 0.5 mM NaN 3 , and 0.2 mM ATP. The N-terminal segment 1 (G1) of gelsolin was recombinantly expressed in Escherichia coli and purified from supernatants of bacterial homogenates [25] . In order to generate the actin:G1 complex, both proteins were mixed at equimolar concentration in G-buffer [26] .
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NET-degradation assay
NET-degradation was analyzed according to the protocol of Hakkim NETs were incubated with diluted plasma for 6 hours at 37°C with 5% CO 2 and humidity. NET-degradation was stopped by replacing the diluted plasma with 2% paraformaldehyde (PFA, Sigma-Aldrich) in PBS. After incubation for 1 hour at RT, the plates were washed twice with PBS. Nuclei and NETs were then labeled fluorescently by adding 2 µM of the DNA dye SytoxGreen (Life Technologies). The total fluorescence of each well was quantified using a fluorometer (Tecan Genios).
Images of fluorescently stained nuclei and NETs were acquired with an inverted fluorescence microscope (Zeiss Axiovert 200M).
Single radial enzyme diffusion (SRED) assay
We quantified DNase activity by the SRED assay [27] . This involved agarose gels containing fluorescent double-stranded DNA being prepared by dissolving 0.13 mg/ml DNA from salmon testes (Sigma-Aldrich) in buffer with 100 mM MES pH 6.5, 20 mM MgCl 2 , 2 mM CaCl 2 , and 2x SYBR Safe (Life Technologies). The DNA solution was heated at 50°C for 10 min and mixed with an equal volume of 2% agarose GP-36 (Nacalai Tesque). The mixture was poured into trays and stored at RT until solidification. Two µl of sample were applied to wells of 1.0 mm radius. After 24 hour incubation at 37°C in a humid chamber, the fluorescence of the gels was recorded with a fluorescence scanner (Molecular Imager FX, Bio-Rad). Image J (NIH) was used for the quantification of signal intensity and the radius of the circles reflecting DNase activity.
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Denaturing SDS-PAGE zymography (DPZ)
To characterize DNases we applied the DPZ method [28] . In brief, SDS-PAGE gels were prepared with 4% (v/v) stacking gels without DNA and 12% (v/v) resolving gels containing 200 µg/ml of salmon testes DNA. Two µl of plasma were mixed with 5 µl of water and 5 µl SDS gel-loading buffer (BioRad), boiled for 5 minutes, and loaded onto the gels. PageRuler Prestained Protein Ladder (MBI Fermentas) was used as molecular marker. Electrophoresis was carried out at 120 V using Tris⁄glycine electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, pH 8.7). After electrophoresis, SDS was removed by washing the gels with 10 mM Tris/HCl pH 7.8 for 30 min at 50°C twice, and the proteins were refolded by incubating the gels overnight at 37°C in a solution containing 5% (w/v) milk powder, 10 mM Tris/HCl pH 7.8, 3 mM CaCl 2 , 3 mM MgCl 2 , 100 U/ml penicillin and 100 µg/ml streptomycin. Next, the gels were transferred to a buffer containing 10 mM Tris/HCl pH 7.8, 3 mM CaCl 2 , 3 mM MgCl 2 , 100 U/ml penicillin, 100 µg/ml streptomycin and 1x SYBR Safe. Gels were incubated for 12 hours at 37°C and fluorescence was recorded by a fluorescence scanner. Image J was used for the quantification by measuring the intensity of bands.
Statistical evaluation
Statistical analysis was performed using Prism Software (GraphPad) and included mean ± SD, linear regression analysis, paired t-test, Mann-Whitney test, Kruskal-Wallis test with Dunn's post hoc test and results were considered significant at p < 0.05. Spearman's rank correlation coefficients were calculated with Bonferroniadjusted significance levels and considered significant at p < 0.005.
Results

Plasma from healthy donors degrades NETs efficiently
We speculated that the microvascular thrombotic process in patients with TMA is linked to a defect in the degradation of NETs. To test our hypothesis, we compared the stability of NETs after exposure to TMA patient plasma or plasma from healthy controls. We incubated purified neutrophils from healthy donors, which had been activated to release NETs, with 5% citrated plasma from healthy control donors or buffer for 6 hours. NET-degradation was measured by two approaches. In the first method, we fluorescently labeled the DNA of neutrophils and
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NETs and analyzed the samples by fluorescence microscopy. In samples containing buffer, NETs were identified as elongated DNA fibers and nuclei as dots ( Fig. 1A) . Incubation with plasma from healthy control donors dissolved NETs, but not the nuclear staining pattern ( Fig.   1B , C). A similar staining was observed using anti-DNA antibodies instead of fluorescent DNA dyes ( Fig. S1 ). To assess NET-degradation quantitatively, we measured the fluorescence intensity after incubation with plasma. We observed a concentration dependent decrease of the DNA fluorescence ( Fig. 1D ). DNA fluorescence reached a minimum at plasma concentrations of 2.5% or higher. At these concentrations the DNA fluorescence is reduced by 75% (Fig. 1D ). The remaining 25% DNA-fluorescence is emitted from nuclei rather than NETs ( Fig. 1B , shaded area in Fig. 1D ). Taken together, these results indicate that NETs are more sensitive to digestion by plasma than neutrophil nuclei and that plasma from healthy donors degrades NETs efficiently.
NET-degradation by plasma from TMA patients is impaired
Next, we explored the effect of TMA patient plasma on NETs. We analyzed citrated plasma from 27 patients with acute TMAs of various etiologies (Table S1 ). We tested plasma collected from 3 patients with enteropathogenic E.coli-associated HUS, 8 patients with acute acquired TTP, 7 patients with tumor-associated TMA, and 9 patients with TMAs of unknown etiology as well as control plasma obtained from 10 healthy donors. Neutrophils, which had been activated to release NETs, were incubated for 6 hours with 5% patient plasma, plasma from healthy control donors or buffer. NET-degradation was analyzed by microscopy and quantified by measuring the intensity of DNA fluorescence. We observed complete degradation of NETs by all 10 control plasma samples, whereas NETs were still visible after exposure to plasma from 21 of 27 TMA patients ( Fig. 2A ). Quantification of DNA fluorescence intensity revealed that plasma from healthy controls, but not TMA patient plasma, decreased the DNA fluorescence by 75% compared to samples incubated with buffer ( Fig. 2B) . These data suggest that plasma-mediated degradation of NETs is reduced in patients with acute TMAs of various etiologies.
DNase activity is decreased in TMA patient plasma
Double-stranded DNA fibers are the major structural component of NETs and make NETs sensitive to digestion by DNases [29] . DNases require calcium and magnesium cations for optimal activity and NETs were stable when incubated with plasma in the presence of EDTA, a calcium and magnesium chelator ( Fig. S1 ). We therefore analyzed whether DNase activity
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in plasma from TMA patients is reduced compared to healthy control donors. Plasma DNase activity was measured by the SRED assay [27] . In this method, plasma is loaded onto an agarose-gel, which contains fluorescently labeled double-stranded DNA. Degradation of DNA by plasma DNases, which diffuse into the agarose gel, can be quantified by a decrease in fluorescence intensity. These experimental conditions allow the quantification of very low levels of DNase activity [30] . Using a standard curve of rhDNase1, we estimated the average DNase activity in citrated plasma from healthy control donors to be 0.32 ± 0.21 mU/ml (n = 10, ± SD), which is within the range of previously reported DNase activities in human serum [27] . Because our study included plasma samples stored at -70°C for several years, we questioned whether freeze-thawing or prolonged storage of plasma reduces DNase activity.
We analyzed plasma collected from healthy donors. We observed similar DNase activities in fresh plasma, plasma subjected to 20 freeze-thawing cycles and plasma stored at -70°C for at least 7 years (data not shown), indicating that enzymatic activity of DNase is not compromised by our storage conditions. Analysis of plasma from patients with acute TMA showed a significant reduction in DNase activity compared to healthy controls (Fig. 3A) . We observed DNA fluorescence of 50% or higher, indicating strong inhibition of NETdegradation, only in samples containing 0.12 mU/ml or less of DNase activity (Fig. 3B ).
Decreased DNase activity was also associated with increased levels of DNA [15] in these samples (Table S1 ; DNA vs DNase1, Spearman r: -0.41, p = 0.01) suggesting that reduced DNase activity may lead to higher levels of NET-markers in patients with acute TMA.
NET-degradation requires plasma DNase1 activity
DNase1 and DNaseγ are the predominant extracellular DNases in circulation [31] . To test which DNase is required for NET-degradation, we pre-incubated plasma with monomeric actin, which inhibits the enzymatic activity DNase1 but not DNaseγ [32] . We supplemented plasma from healthy controls with the complex of monomeric actin with gelsolin segment 1 (G1). G1 keeps actin in its monomeric state, prevents actin polymerization in plasma and thus maintains the DNase1-inhibitory activity of actin [26] . Actin:G1 supplemented plasma showed no NET-degrading activity indicating that NETs are degraded by plasma DNase1 (Fig. 4A, B ).
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Levels of active DNase1 are decreased in TMA patient plasma
We now analyzed whether impaired NET-degradation by TMA patient plasma is due to reduced levels of DNase1 in plasma. To detect DNase1 in human plasma, we employed commercially available techniques including an ELISA and Western blotting based on a polyclonal antibody against DNase1. However, both approaches failed to detect DNase1 in plasma from control donors due to a lack of sensitivity or specificity, respectively (Fig. S2 ).
Therefore we quantified DNase1 levels in human plasma by denaturing SDS-PAGE zymography (DPZ) method [28] , instead of antibody-based techniques. The DPZ method separates SDS-denatured plasma proteins in a polyacrylamide gel, which contains DNA. Refolding of the proteins after SDS elution restores the enzymatic activity of DNases.
Fluorescent staining of DNA in the gels detects DNase activity as an unlabeled band. DPZ analysis of plasma from healthy controls revealed a single protein band with DNase activity of approximately 38 kDa (DPZ in Fig. 5A ). The size of this DNase is within the reported size of DNase1 in human serum [33] . Using this approach, we quantified strongly reduced levels of active DNase1 in TMA patient plasma compared to healthy controls (Fig. 5A, 5B ).
DNase1 detected by the DPZ assay is, unlike the SRED method, not sensitive to inhibition by actin. The addition of actin:G1 to plasma dose-dependently blocked DNase1 activity detected by the SRED assay, but had no effect on DNase1 measured by DPZ (Fig. 5C, 5D ).
Interestingly, plasma DNase1 activities determined in TMA patients by the DPZ and SRED assay are strongly correlated (Fig. 5E ) indicating that the reduction of DNase1 activity is not due to an inhibitor but a result of lower DNase1 levels.
RhDNase1 restores NET-degradation by TMA patient plasma
Finally, we questioned whether NET-degradation activity of TMA patient plasma can be restored by supplementing plasma with rhDNase1. We mixed TMA patient plasma with 0.5 mU/ml rhDNase1. Analysis by the SRED assay showed that the addition of rhDNase1 restored DNase activity in TMA patient plasma to levels detected in healthy control donors ( Fig. 6 A, B) . Analysis by NET-degradation revealed that the supplementation with rhDNase1 enables TMA patient plasma to degrade NETs efficiently ( Fig. 6 C, D) . We furthermore analyzed whether plasma from healthy donors could serve as a source of DNase1 and restore NET-degradation by TMA patient plasma. Indeed, supplementing plasma from TMA patients with a pool of plasma from healthy donors at a 1:1 ratio (v/v) enabled NET-degradation ( Fig. 
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This article is protected by copyright. All rights reserved. 6 C, D). In summation, these data indicate that the defect in DNase1-mediated NETdegradation can be restored by rhDNase1 or plasma from healthy donors.
Discussion
Our data suggests that lowered levels of plasma DNase1 lead to an impaired NETdegradation in vitro and are associated with acute TMAs. We speculate that a reduction in 
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humans was believed to originate from the pancreas [33] . However, DNase1 is produced by the exocrine part of the pancreas [40] , which most likely excludes a direct secretion into circulation. Interestingly, hepatocytes are a major source of plasma DNase1 in mice [41] .
Future studies may identify the origin of plasma DNase1 in humans and generate animal models, which specifically lack DNase1 in circulation, to study the role of plasma 
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